New drug with chemotherapy and immunotherapy for stomach cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This study tests a new drug (BioTTT001) combined with chemotherapy (SOX) and an immunotherapy drug (toripalimab) for patients with stomach cancer that has spread to the lining of the abdomen. The goal is to see if this combination is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You have stomach cancer that has spread to the lining of the abdomen (peritoneum).
- You have not had systemic treatment for this cancer, or if you had chemotherapy before surgery, it must have been more than 6 months ago.
- Your cancer must be HER2-negative, meaning it does not have a specific protein that some treatments target.
- You need to have at least one tumor that can be measured on a scan.
- Your blood counts, liver, kidney, and heart function must be within acceptable ranges for the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug combination (BioTTT001, toripalimab, and regorafenib) for people with colorectal cancer that has spread to the liver and has not responded to earlier treatments. The goal is to see if this combination can shrink tumors and help patients live longer.
This trial studies toripalimab (an immune system medicine) plus FLOT chemotherapy in people with stomach cancer that has grown locally but hasn’t spread to distant organs. It aims to improve control of the cancer and help more people have their tumors fully treated.
This study tests a treatment approach for stomach cancer that hasn't spread to other organs. It's for people who have not had any prior cancer treatments and are in relatively good health.
This trial compares three different treatment combinations for advanced stomach cancer that hasn't spread to the brain and is HER2-negative. It includes an immunotherapy drug (sintilimab) with different chemotherapy backbones, and one option adds a targeted therapy (lenvatinib). The goal is to see which combination works best and has acceptable side effects.
This study tests a combination of three treatments—JS107, toripalimab (an immunotherapy), and chemotherapy—for advanced stomach cancer that has a specific protein marker called CLDN18.2. The goal is to see if this combination can shrink tumors and help patients live longer.
This study tests a combination of two treatments for stomach cancer that has spread to the lining of the belly. It uses an immunotherapy drug (tislelizumab) plus standard chemotherapy (SOX) and a heated chemotherapy treatment directly into the belly (HIPEC) to see if this approach is safe and effective.
Hear when a new Gastric Cancer, Metastatic trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.